Re:NewCell AB (publ)
STOCKHOLM, SE / ACCESSWIRE / November 1, 2021 / Re:NewCell AB (publ) (FRA:6QP) (STO:RENEW)
Re:NewCell AB (publ) ('Renewcell') will publish its interim report for the third quarter 2021 on Friday, November 5, at around 08.00 (CEST). On the same day, at 10.00 (CEST) Renewcell's CFO Hugo Petit will join Infront Direkt for a livestreamed Report Commentary.
The live broadcast will be available afterwards on-demand. The broadcast will be held in English. The report and presentation material will be made available on Renewcell's website www.renewcell.com.
Link to the broadcast: https://www.youtube.com/watch?v=45afHdmSfZA
Contact
Hugo Petit
Chief Financial Officer
investors@renewcell.com
+46 70 7787196
About Renewcell
Founded by innovators from Stockholm's KTH Royal Institute of Technology in 2012, Re:NewCell AB (publ) (‘Renewcell') is a multi-award-winning sustaintech company based in Sweden. The company's vision is to inspire an Industrial Evolution to a sustainable world by producing high quality materials from recycled textiles.
Through its patented process, Renewcell is able to upcycle cellulosic textile waste, such as cotton clothes, transforming it into a pristine new material called Circulose®. Fast Company named Renewcell one of the World's Most Innovative Companies 2021. Circulose® was also included on TIME Magazine's list of the 100 Best Inventions 2020.
Renewcell is a publicly listed company with shares traded on Nasdaq First North Premier Growth Market with the ticker name RENEW and ISIN code SE0014960431. FNCA Sweden AB is Renewcell's Certified Adviser, +46(0)8-528 00 399, info@fnca.se.
SOURCE: Re:NewCell AB (publ)
View source version on accesswire.com:
https://www.accesswire.com/670524/Invitation-to-Report-Commentary-for-Renewcells-interim-report
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Cambridge Isotope Laboratories, Inc. Unveils ISOAPI-D - a New Standard in Deuterated Reagents for Pharmaceutical Innovation - at CPhI Frankfurt 202527.10.2025 14:00:00 CET | Press release
With ISOAPI-D, CIL offers pharmaceutical partners a secure, global supply of deuterated reagents - manufactured to the highest quality standards for faster, more efficient API development. TEWKSBURY, MASSACHUSETTS / ACCESS Newswire / October 27, 2025 / Cambridge Isotope Laboratories, Inc. (CIL), a global leader in stable isotope chemistry, announces the launch of ISOAPI-D™, a unified brand of deuterated intermediates for API synthesis. The new ISOAPI-D brand will be launched at CPhI Frankfurt, where CIL welcomes industry professionals to stand #2.0G2 from October 28-30.ISOAPI-D ISOAPI-D Power of Deuterium: Smarter, Stronger Therapeutics "ISOAPI-D reagents are designed to support the development of next-generation active pharmaceutical ingredients (APIs) by leveraging the unique benefits of deuterium incorporation," said Cliff Caldwell, CEO of CIL. "With ISOAPI-D, our customers gain access to a trusted and secure supply chain, ensuring they have consistent, reliable access to the materi
Cambridge Isotope Laboratories, Inc. and Chemtatva Chiral Solutions Pvt. Ltd. to Establish Cambridge Isotope Laboratories, Pvt. Ltd. in Hyderabad, India27.10.2025 13:45:00 CET | Press release
Strategic Partnership to Establish Cambridge Isotope Laboratories, Pvt. Ltd. in Hyderabad's Genome Valley, Enhancing Global Production and Supply of Isotopically Enriched Chemical Solutions for Pharmaceutical and Electronics Industries TEWKSBURY, MA AND HYDERABAD, INDIA / ACCESS Newswire / October 27, 2025 / Cambridge Isotope Laboratories, Inc. (CIL), and Chemtatva Chiral Solutions, Pvt. Ltd. (CCS), a leading provider of chiral and specialty chemical solutions, announce the execution of a signed Memorandum of Understanding to establish Cambridge Isotope Laboratories, Pvt. Ltd. in Hyderabad, India. This initiative marks a milestone in the expansion of CIL's global footprint and further enhances capabilities in the development and production of deuterated reagents and other isotopically enriched products. This partnership will enhance global supply chain strength and real-time support for customers in Asia and enable multi-site production for global customers focused on business continui
Sauce Labs and Deque Systems Partner to Deliver Comprehensive Accessibility Testing at Scale24.10.2025 07:00:00 CEST | Press release
SAN FRANCISCO, CA / ACCESS Newswire / October 24, 2025 / Sauce Labs Inc., a leading provider of continuous testing solutions, and Deque Systems, Inc., a trusted leader in digital accessibility, today announced a strategic partnership to help companies ensure compliance with accessibility regulations and deliver accessible digital experiences across all devices and platforms. The collaboration combines Sauce Labs' extensive real-device coverage and scalable cloud infrastructure with Deque's unparalleled accessibility expertise. This partnership is a renewed commitment, building on a long-standing relationship between the two companies. By doubling down on their joint offering, Sauce Labs and Deque are providing a comprehensive solution for accessibility testing at scale. The partnership addresses the growing need for businesses to meet digital accessibility standards, especially with the upcoming European Accessibility Act (EAA), which became law on June 28, 2025. The EAA requires produ
Florence Connects 65,000+ Study Sites and 600+ Sponsors Worldwide - Unleashing the Next Era of Clinical Trial Intelligence23.10.2025 14:00:00 CEST | Press release
With the industry's largest network of sites, Florence sets a new benchmark for AI-enabled study startup, workflow automation, and operational risk management. ATLANTA, GA / ACCESS Newswire / October 23, 2025 / Florence Healthcare reinforced its position as the global leader in clinical trial operations with a major milestone: Florence Trial Operations Platform now connects 65,000 study sites spanning more than 600 sponsors across 90+ countries, forming the industry's largest network. Recognized as the #1 clinical trial technology for six consecutive years, Florence continues to set the standard for startup speed, workflow automation, and operational risk management across sponsor study portfolios. "Florence was built to bring sponsors and sites into a shared operational space," said Ryan Jones, CEO of Florence Healthcare. "First, we fully digitized startup to eliminate manual bottlenecks and paper workflows. Now, we're using AI to enhance speed and augment intelligence across 65,000 s
U.S. Polo Assn. Wins Gold and Silver Stevie Awards at the 2025 International Business Awards in Lisbon, Portugal23.10.2025 13:00:00 CEST | Press release
LISBON, PT AND WEST PALM BEACH, FL / ACCESS Newswire / October 23, 2025 / USPA Global today announced that U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), has been awarded two prestigious Stevie® Awards from the 22nd Annual International Business Awards® (IBA).U.S. Polo Assn. Wins Two Stevie® Awards U.S. Polo Assn. was celebrated during an elegant gala event at the Corinthia Hotel in Lisbon, Portugal, on Friday, October 10, attended by leadership from USPA Global and the brand's strategic partners in the region. The global event hosted over 350 guests from more than 30 nations, including many of the world's top companies and Stevie winners, including Coca-Cola, Starbucks, Lenovo, Kendra Scott, IBM, and Turkish Airlines. The brand's winning entries included a Gold Stevie Award for 'Achievement in International Expansion' and a Silver Stevie Award in 'Celebration Event' for the 2024 Paris Games Polo Challenge campaign. The multi-billion-dollar, sp
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom